Trial Profile
A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs ARX 788 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Bladder cancer; Colorectal cancer; Gastric cancer; HER2 positive breast cancer; Male breast cancer; Non-small cell lung cancer; Oesophageal cancer; Salivary gland cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms ACE-Pan Tumor-01
- Sponsors Ambrx
- 31 Jan 2024 Status changed from active, no longer recruiting to completed.
- 09 Dec 2023 Results (n=42) in breast cancer patients , presented at the 46th Annual San Antonio Breast Cancer Symposium
- 06 Apr 2023 Planned End Date changed from 1 Sep 2023 to 1 Dec 2023.